ovarian cancer

News

PMV cues up filing for first p53-directed cancer therapy

PMV is preparing to file for approval of its first-in-class oral p53 protein reactivator, rezatopopt, for ovarian cancer in the first quarter of 2027.

Oncology

Solving the ovarian cancer diagnostic and treatment pathway ...

News

Moderna shows in vivo CAR-T hand in R&D update

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities.

News

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.

News

Data backs GSK's ovarian cancer blockbuster hopes

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

News

Corcept gets FDA OK for first-in-class ovarian cancer drug

Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

PMV cues up filing for first p53-directed cancer therapy

Solving the ovarian cancer diagnostic and treatment pathway ...

Moderna shows in vivo CAR-T hand in R&D update

AbbVie's ovarian cancer drug Elahere gets NHS green light

Data backs GSK's ovarian cancer blockbuster hopes

Corcept gets FDA OK for first-in-class ovarian cancer drug

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

ovarian cancer

Editor's Picks